<DOC>
	<DOCNO>NCT00005618</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . PURPOSE : Phase II trial study effectiveness arsenic trioxide treat patient relapsed refractory chronic myelogenous leukemia .</brief_summary>
	<brief_title>Arsenic Trioxide Treating Patients With Relapsed Refractory Chronic Myelogenous Leukemia</brief_title>
	<detailed_description>OBJECTIVES : I . Determine antileukemic efficacy arsenic trioxide patient relapse and/or refractory , chronic , accelerate , blastic phase chronic myelogenous leukemia . II . Determine pattern clinical adverse experience patient population administer drug . OUTLINE : Patients stratify accord disease stage ( chronic phase v accelerate phase blastic phase ) . Patients receive arsenic trioxide IV 1 hour consecutive day weekdays total 25 day follow 3-5 week rest . Treatment continue maximum 6 course absence unacceptable toxicity disease progression . Patients respond disease follow least monthly . PROJECTED ACCRUAL : A total 10-27 patient accrue chronic phase stratum study within 2 year . A total 17-37 patient accrue accelerated blastic phase stratum study within 2 year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Arsenic trioxide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Chronic myelogenous leukemia ( CML ) confirm : Cytogenetic test demonstrate presence ( 9:22 ) OR RTPCR demonstrate presence BCR/ABL rearrangement Chronic phase Blast count le 15 % OR Accelerated phase define 1 following : Blast count great 15 % le 30 % Blast count promyelocytes great 30 % Basophils great 20 % Thrombocytopenia le 100,000/mm3 related therapy Cytogenetic clonal evolution ( 13 ) OR Blastic phase Blast count great 30 % OR Evidence extramedullary blast Relapse failure achieve major cytogenetic response least 1 course standard antiCML therapy include interferon alfa cytotoxic chemotherapy Must fail adequate trial interferon alfa unless intolerance contraindication interferon alfa Not eligible allogeneic stem cell transplant PATIENT CHARACTERISTICS : Age : Not specify Performance status : Karnofsky 70100 % Life expectancy : Not specify Hematopoietic : See Disease Characteristics Hepatic : Bilirubin great 1.5 time upper limit normal ( ULN ) Renal : Creatinine great 1.5 time ULN Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 4 month study No active serious infection control antibiotic PRIOR CONCURRENT THERAPY : Biologic therapy : See Disease Characteristics At least 4 week since prior interferon alfa Chemotherapy : See Disease Characteristics At least 4 week since prior chemotherapy ( 1 day hydroxyurea ) No concurrent chemotherapy Endocrine therapy : Not specify Radiotherapy : No concurrent radiotherapy Surgery : Not specify Other : No concurrent investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2001</verification_date>
	<keyword>relapse chronic myelogenous leukemia</keyword>
	<keyword>chronic phase chronic myelogenous leukemia</keyword>
	<keyword>accelerated phase chronic myelogenous leukemia</keyword>
	<keyword>blastic phase chronic myelogenous leukemia</keyword>
</DOC>